Vanderbilt Health — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$37,343	4
2024	Research	$54,220	1
2023	Research	$71,737	1
2021	Research	$235,293	3
2020	Research	$112,044	3

Breakdown

Who paid Research payments · program years 2020–2025

Pfizer Inc. $347,337 6 payments
Alexion Pharmaceuticals, Inc. $126,193 3 payments
AstraZeneca UK Limited $37,108 3 payments

Studies the money was for Research payments · program years 2020–2025

Palbociclib and Endocrine Therapy for Lobular Breast Cancer Preoperative Studya Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma $347,337 6 payments
An Observational, Longitudinal, Prospective, Long term Registry of Patients with Hypophosphatasia $126,193 3 payments
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 $25,655 1 payment
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) $10,744 1 payment
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease $709 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.